Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jul 16;6:61. doi: 10.1038/s41525-021-00226-4

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 1 — Each vertical bar corresponds to a single tumor. Top track: The mutation burden (mutations per megabase) of each tumor. Middle track: The fraction of mutations within each tumor matching the canonical UV radiation signature. Bottom track: The fraction of mutations attributable to established mutational signatures within each tumor. The proposed etiology of select signatures is indicated. XP = tumors from patients with xeroderma pigmentosum, Sporadic = tumors from patients with no known comorbidities, immunosuppressed: tumors from immunosuppressed patients—this group is further stratified by the usage or absence of azathioprine as an immunosuppressive drug, RDEB = tumors from patients with recessive dystrophic epidermolysis bullosa.